Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

 Americans turn the low-fat way



12th August, 2005:
With two-thirds of Americans becoming overweight, the $550 billion processed food industry in the country is increasingly going for whole grains, fiber and fish oil. Currently, food scientists of every major player in the food-ingredients sector are reportedly working on ways to find products that have less fat, white flour, sugar and salt.

Figures indicate that foods labeled as healthy like Baked Lay's potato crisps, Tropicana orange juice, Diet Pepsi and Quaker oatmeal are growing at double the pace of other products.

In their efforts to develop healthier stuffs, several of the firms have come out with amazing results. Proteus Industries in Gloucester, Mass, for instance, has introduced low-fat fried chicken. The chicken contained 50 per cent less fat than a typical piece of fried chicken.

Food ingredient companies today sell $4 billion worth of additives to the food industry a year. Additives are responsible for many of the common properties of processed food. Additives, for instance, keep the fruit in yogurt suspended, not plopped at the bottom. They make sure that chicken dinners do not come out of the microwave hot around the edges and cold in the middle, and they allow many foods to stay in warehouses or on supermarket shelves for up to nine months without spoiling. 

Tate & Lyle of London, one of the largest food-ingredient companies in the world, makes the popular sweetener Splenda. It recently started selling a whole-grain "cracker system" composed of Splenda and hydrolyzed wheat protein, an additive that has been manipulated - either chemically or through enzymes - to give the softness of white flour without adding carbohydrates. 

Other ingredient companies are focusing on what they can add to food to make it healthier. Both Cargill, the commodities giant that has a large food-ingredient business, and National Starch Food Innovation, the food arm of National Starch and Chemical based in Bridgewater, N.J., and itself a unit of the giant Imperial Chemical Industries of Britain, have seized upon the fact that the average American consumes less than half the fiber each day that the government recommends. 

Nutritionists consider fiber beneficial because it prompts slower, steady digestion, preventing spikes in blood sugar and insulin. It has also been shown to lessen the risk of colon cancer. 

Omega-3 fatty acids, which studies have shown to protect against heart disease and are essential for brain development in infants, is another ingredient that food companies are clamoring over. Last September, the FDA. approved the health claim for omega-3 that it may reduce the risk of heart disease. The best source of omega-3's is the oil in fish. But fish oil is, well, fishy, and is not a natural fit for inclusion in the likes of bread, muffins and cereal bars. To deal with this, National Starch recently perfected technology that encapsulates fish oil, so it can be added to foods without an unappealing taste or smell. 
Kellogg has signed a 15-year licensing deal with Martek Biosceinces company that sells omega-3 fatty acids derived from algae, which have a milder smell and do not necessarily need to be encapsulated. Kellogg declined to comment on the deal or when the algae-based omega-3's might appear in its products. 

However, food companies maintain that their consumer research shows that convenience and taste still outrank nutrition as the top priority for most people and that consumers have no intention of giving up their favorite foods. 

If Americans stopped eating large quantities of fried chicken, sweetened breakfast cereal, cookies and snack chips, the financial health of many companies would suffer. 
And that is why food firms like Proteus Industries keep searching for the perfect recipe for low-fat chicken.


Pharma News Headlines

Cancer News

Cardiac News


Pharma industry news


Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

Pfizer files NDA for Sutent in US

BioVeris licenses Baxter's vaccine portfolio

TheraQuest receives 2nd Orphan Drug status for neuralgia drug

Real-time glucose monitoring device approved in US

Halozyme gets FDA nod for bladder cancer therapy

Migenix to commence phase 2b studies in hep C therapy

Barr gets US FDA okay for clonazepam tabs

Anorexia drug study results positive: Par

GlaxoSmithKline begins phase III trials of new HIV drug

Ranbaxy's 7 anti retrovirals included in WHO list

FDA tightens restrictions on acne drug

Voglibose tabs launched in Japan

Remicade researcher gifts $ 105m to NYU

Par loses ondansetron case to GSK

Mistral starts clinical studies for generic

Carl Icahn sells Mylan shares

Florida sues Mylan, Teva and Watson

Dey and Connecticut settle pricing dispute

Germany set to stop rabies crossing borders

Office to review DTC drug advertisements in US

British docs to be trained in communication, safety

FDA okays acrylic lens for cataract patients 

Corautus to go ahead with angina drug studies 

Americans turn the low-fat way

Chemicals in plastics pose danger

US committee probes doctors’ complicity with Wall Street analysts

Meda buys out rival Viatris

US FDA nod for new levofloxacin regimen to treat acute bacterial sinusitis

Pozen files for new migraine treatment

New therapy for pancreatic cancer under review

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers



Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us